期刊文献+

晚期前列腺癌药物去势中Gleason评分、血清PSA与疗效相关性研究 被引量:2

A relative analysis on the efficacy of medical castration in the treatment of metastatic prostate cancer patients to Gleason score and serum PSA level
下载PDF
导出
摘要 目的:探讨晚期前列腺癌(Pca)患者药物去势治疗过程中疗效与Gleason评分及血清前列腺特异性抗原(PSA)的相关性。方法:选择33例晚期Pca患者,给予黄体激素释放激素类似物(LHRH—A)+抗雄激素药物进行药物去势治疗,根据Gleason评分分为2~5分组、6~7分组、8~10分组,对3组血清PSA变化进行分析。结呆:Gleason评分6~7分组的病人在治疗后3个月内血清PSA值下降最快,治疗后6个月时Gleason评分2~5分组病人血清PSA值恢复正常,而Gleason评分6~7分组与8~10分组病人血清PSA值则接近正常值范围。不同Gleason评分组间血清PSA水平差异有统计学意义(F=5.396,P〈O.05)。结论:(1)Gleason评分、血清PSA水平与晚期Pca患者行药物去势疗法疗效有密切关系。(2)血清PSA变化是监测Pca复发与评价疗效的可靠瘤标。 Objective. To probe into the correlation of Gleason score and serum PSA level during medical castration in metastatic prostate cancer patients. Methods. We treated metastatic prostate cancer patients with luteinizing hormone-releasing hormone analog, (LHRH-A) and androgen ablation drug (Flutamide), and combined with the change of Gleason score and serum PSA level, We have a statistical analysis elevate the efficacy of treatment. Results. The levels of the serum PSA during the treatment significantly decreased in 3 months among the groups of Gleason score between 6-7. The level of the serum PSA during the treatment returned to normal in 6 months among the groups of Gleason score between 2-5, but the groups of Gleason score between 6-7 and 8-10 were near to normal and the level of serum of PSA among different groups of Gleason score with significantly different (F = 5. 396, P 〈0.05). Statistically signifi- cant differences were found in those. Conclusions: (1) The Gleason score and the level of the serum PSA have a close relation to the efficacy of medical castration in the treatment of metastatic prostate cancer patients. (2)The change of PSA level is a valuable marker for watching the recurrent and effective of tumor.
出处 《新疆医科大学学报》 CAS 2007年第1期46-47,50,共3页 Journal of Xinjiang Medical University
关键词 前列腺癌(Pca) 前列腺特异性抗原(PSA) GLEASON评分 prostate cancer (Pca) prostate specific antigen(PSA) Gleason score
  • 相关文献

参考文献5

  • 1Weir EG,Partin AW,Epstein JI.Correlation of serum prostate specific antigen and quantitative immunohistochemistry[J].Urol,2000,163:1739-1742.
  • 2Bostwick DG,PaceliA,Blute M,et al.Prostate specific membrane antigen expression in prostatic in traepithelial neoplasia and adenocarci noma:a study of 184 cases[J].Cancer,1998,82(11):2256-2261.
  • 3Froschermaier SE,Pilarsky CP,Wirth MP.Clinical significance of the determination of noncomplexed prostate specific antigen as a mark er for prostate carcinoma[J].Urology,1996,47(4):525-528.
  • 4王海东,董胜国,张平,丛榕.PSA和PCNA在前列腺癌中的表达及意义[J].齐鲁医学杂志,2004,19(1):36-38. 被引量:4
  • 5Pannek J,Rittenhouse Ⅱ G,Chan DW.et al.The use of precent free prostate specific antinen for staninn clincally localized prostate cancer[J].J L rol,1998,159:1238-1249.

二级参考文献6

  • 1姚根有,耒茂德,陈培辉.前列腺癌组织的免疫细胞化学观察[J].中华医学杂志,1994,74(3):161-162. 被引量:3
  • 2Nemoto R,Kawamura H,Miyakawa I,et al.Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma[J].J Urol,1993,149:165.
  • 3Spires SE, Banks ER, Davey DD. Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators[J]. Urology, 1994,43(5):660.
  • 4Okano M. The histological expression of prostate-specific antigen and its clinical significance in patients with prostate cancer[J]. Nippon Hinyokika Gakkai Zasshi, 1990,81(6):847.
  • 5Morris GF,Mathews MB.Regulation of proliferating cell nuclear antigen during the cell cycle[J]. J Biol Chem,1989,264:13856.
  • 6Brabo R,Macdonalc-bravo H. Existense of two populations of cyclin/ proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites [J].J Cell Biol,1987,105(4):1549.

共引文献3

同被引文献33

  • 1彭志强,钟惟德,何慧婵,江福能,刘文华,戴奇山,蔡岳斌,谢克基,欧汝彪,李俊玲,刘良式,魏鸿蔼.雄激素受体AR表达在前列腺癌诊断中的意义[J].广州医学院学报,2005,33(2):55-57. 被引量:2
  • 2姜涛,李先承,宋希双,姜辉,张平萍.雄激素受体在前列腺癌中表达和意义的探讨[J].中国男科学杂志,2005,19(6):29-32. 被引量:6
  • 3夏雪雁,李连宏,李先承,姜涛.凋亡抑制基因Survivin和抑癌基因PTEN在前列腺癌组织中的表达及临床意义[J].中华男科学杂志,2006,12(4):346-348. 被引量:17
  • 4许克新,王晓峰,佟雪松.血清PSA与Gleason分级及临床分期的相关性研究[J].中国男科学杂志,2007,21(5):31-34. 被引量:7
  • 5Beyer DC,Thomas T,Hilbe J.Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.Brachytherapy,2003,2:77-84.
  • 6Kishi H,Igawa M,Kikuno N,et al.Expression of the Survivin gene in prostate cancer:correlation with clinicopathological charaeteristics,proliferative activity and apoptosis.J Urol,2004,171:1855-1860.
  • 7Shariat SF,Lotan Y,Saboorian H,et al.Survivin expression is associated with features of biologically aggressive prostate carcinoma.Cancer,2004,100:751-757.
  • 8Robnett TJ, Whittington R, Malkowicz SB, et al. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. Int J Radiat Oncol Biol Phys, 2002, 53(5) : 1146-1151.
  • 9Weller PA, Ogryzko EP, Corben EB, et al. Complete sequence of human vinculin and assignment of the gene to chromosome 10. Proc Natl Acad Sci USA, 1990, 87(15) : 5667-5671.
  • 10Perez-Castineira JR, Lopez-Marques RL, Villalba JM, et al. Functional complementation of yeast cytosolic pyrophosphatase by bacterial and plant H^+ translocating pyrophosphatase. Proc Natl Acad Sci USA, 2002, 99(25) : 15914-15919.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部